Compare MAT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAT | TMDX |
|---|---|---|
| Founded | 1945 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.6B |
| IPO Year | 1994 | 2019 |
| Metric | MAT | TMDX |
|---|---|---|
| Price | $16.20 | $129.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $21.11 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 7.9M | 787.7K |
| Earning Date | 05-13-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | 1.24 | ★ 4.87 |
| Revenue | ★ $5,347,623,000.00 | $605,494,000.00 |
| Revenue This Year | $5.99 | $24.12 |
| Revenue Next Year | $5.05 | $18.69 |
| P/E Ratio | ★ $12.93 | $26.95 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $13.95 | $62.42 |
| 52 Week High | $22.48 | $156.00 |
| Indicator | MAT | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 43.67 |
| Support Level | $14.75 | $124.45 |
| Resistance Level | $19.33 | $146.04 |
| Average True Range (ATR) | 0.52 | 8.70 |
| MACD | 0.05 | -1.13 |
| Stochastic Oscillator | 27.27 | 22.48 |
Mattel manufactures and markets toy products that are sold to its wholesale partners and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2025, with the remainder stemming from international markets.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.